- CME/CE Activities
- CER on Angiotensin-Directed Therapies for SIHD
This CME/CE activity is provided by PRIME Education, Inc. (PRIME®) and is accredited for a multi-disciplinary audience of health care practitioners. This activity is supported by contract number HHSA290201200021I from the Agency for Healthcare Research and Quality. User data collected through this activity will reside on PRIME's educational portal for use by AHRQ.
Summary of AHRQ's Comparative Effectiveness Review of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Added to Standard Medical Therapy for Treating Stable Ischemic Heart Disease
- Program Overview
- Faculty Biographies
- Accreditation Statements
- Post-Test & Evaluation
Credit for this CME/CE activity has expired.
You can still access the program, but will not receive a certificate.
Stable ischemic heart disease (IHD) is a condition of advanced atherosclerosis in which affected individuals may be asymptomatic or may experience debilitating symptoms, including angina and diminished activity tolerance. Stable IHD significantly increases the risks of nonfatal and fatal cardiovascular events. Considerable evidence from clinical trials has demonstrated that standard medical treatments — including antiplatelet therapy, statins, beta-blockers, and vasodilators — partially reduce risks and/or symptoms in patients with stable IHD. The evidence is less clear about the effectiveness of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-II receptor blockers (ARBs), especially in patients with stable IHD who have no history of heart failure or left ventricular dysfunction. For this population a key clinical question is whether, compared with standard medical therapy alone, the addition of an ACEI or ARB is beneficial and safe. Another question involves the benefits and harms of combined regimens of these angiotensin-directed therapies. These questions are central to a systematic research review that was commissioned by the Agency for Healthcare Research and Quality (AHRQ) and published in 2009. The findings and potential clinical applications of the AHRQ review are presented in this educational activity.
At the conclusion of this activity, the participant should be able to:
- Summarize the comparative effectiveness and safety of adding an ACEI or an ARB to standard therapy versus standard therapy alone
- Compare the benefits and harms of ACEI-ARB combined therapy plus standard therapy versus an ACEI or an ARB plus standard therapy
- Identify subpopulations of patients who might benefit from adding an ACEI, an ARB, or combination therapy to standard medical therapy
- Apply relevant findings from the systematic review to guide decisions about appropriate patient-centered therapies for managing stable IHD and reducing risks of cardiovascular events
This CME activity is designed to meet the educational needs of physicians, pharmacists, nurses, case managers.
Method of Participation
To receive a certificate for this activity, you should:
- Complete the learner assessment pretest
- View the entire activity online
- Complete an online evaluation & post-test
- Print your certificate online
The estimated time to complete this activity, including review of the materials, is 1.0 hour.
Term of Approval
May 31, 2011 through May 31, 2013. Original release date: May 31, 2011.
Acknowledgement of Support
There is no fee for this CME/CE activity. This activity is sponsored by PRIME Education, Inc (PRIME®) and funded under contract HHSA290201200021I from the Agency for Healthcare Research and Quality (AHRQ), U.S. Department of Health and Human Services (HHS).
Faculty Biographies and Disclosures
C Michael White PharmD, FCP, FCCP
Professor and Head, School of Pharmacy,
Laurence Greene, PhD
Director of Scientific Education and Outcomes
PRIME Education, Inc.
Frank L Urbano, MD, FACP
Medical Director, Care Management
Albert Einstein Medical Center
Assistant Professor of Medicine
Cooper Medical School of
Heidi Wynn Maloni, PhD, ANP-BC, CNRN, MSCN
National Clinical Nursing Director
Department of Neurology
Multiple Sclerosis Center of Excellence, East Veterans Affairs Medical Center
Trinity Nursing Program School of Professional Studies, Trinity Washington University
Clinical Preceptor and Instructor
Advanced Practice Programs, The Catholic University of America School of Nursing
Gary L Schaer, MD
Professor of Medicine
Director, Cardiac Catheterization Lab
Rush University Medical Center
Kathleen A Jarvis, MS, RN, CCM
Fort Lauderdale, FL
This program is no longer accredited.
|Faculty Name ||Advisory Board||Consultant||Grants / Research||Salary / Contractual||Supported Promotional Education||Stock / Shareholder||Other Financial Support|
|C Michael White PharmD, FCP, FCCP
|Laurence Greene, PhD
|Frank L Urbano, MD, FACP
|Heidi Wynn Maloni, PhD, ANP-BC, CNRN, MSCN
|Gary L Schaer, MD
|Kathleen A Jarvis, MS, RN, CCM
|Chris R Prostko, PhD|
Scientific Program Director
|Lynn Goldenberg, RN, BSN|
Director of Accreditation & Compliance
PRIME Education Inc (PRIME®) endorses the standards of the ACCME, as well as those of the AANP, ANCC and ACPE, that require everyone in a position to control the content of a CME/CE activity to disclose all financial relationships with commercial interests that are related to the content of the CME/CE activity. CME/CE activities must be balanced, independent of commercial bias and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
A conflict of interest is created when individuals in a position to control the content of CME/CE have a relevant financial relationship with a commercial interest which therefore may bias his/her opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks or other financial benefits.
PRIME® willidentify, review and resolve all conflicts of interest that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff are provided with this activity.
Presentations that provide information in whole or in part related to non FDA approved uses of drugs and/or devices will disclose the unlabeled indications or the investigational nature of their proposed uses to the audience. Participants should refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. Participants should verify all information and data before treating patients or employing any therapies prescribed in this educational activity. The opinions expressed in the educational activity are those of the presenting faculty and do not necessarily represent the views of PRIME®, the ACCME, AANP, ACPE, ANCC and other relevant accreditation bodies.
Content validation methods are consistently utilized by PRIME® to ensure that all program content is evidence-based, fair-balanced, and developed with scientific rigor and integrity. All clinical recommendations are based on evidence accepted within the medical profession. All scientific research referred to, reported or used to support a clinical recommendation conforms to accepted standards of experimental design, data collection and analysis. In addition to review of content by course directors and expert faculty, content is also validated through independent peer reviewers selected for their expertise in the content area, as well as their experience in the intended audience. All peer reviewers, planners, course directors, faculty and relevant staff utilized by PRIME® complete disclosures which are related to their role in the educational activity.
PRIME®is committed to providing access to our CME programs for individuals with disabilities as identified in Section 508 of the Rehabilitation Act for all web-based programs. This website is 508 compliant.
1. Access the Activity:
Adobe Acrobat Reader or equivalent is required to view this program.
Open the PDF Activity in New Tab
Post-Test & Evaluation
Credit for this program has expired.
If you already completed this program and need to reprint your certificate(s), login here.
Clinician & Consumer Summaries on ACEIs and ARBs
Download these free summaries for your reference and/or patient handouts. You may also order bulk copies free of charge from the AHRQ Publication Clearinghouse below.